Quarterly ResultMay 7, 2026, 06:13 AM
Generate Biomedicines Q1 Net Loss $(61.7)M; IPO Raises $369.3M
AI Summary
Generate Biomedicines reported a net loss of $(61.7) million for the first quarter of 2026, an increase from $(44.3) million in the prior year period, primarily due to higher research and development expenses. The company successfully completed its Initial Public Offering in March 2026, raising net proceeds of $369.3 million, which significantly improved its liquidity position to $516.6 million in cash, cash equivalents, and marketable securities. This capital infusion alleviated previous concerns about the company's ability to continue as a going concern, with current resources expected to fund operations into the first half of 2028.
Key Highlights
- Net loss for Q1 2026 was $(61.7) million, compared to $(44.3) million in Q1 2025.
- Collaboration revenue for Q1 2026 was $7.2 million, down from $8.8 million in Q1 2025.
- Research and development expenses increased to $57.8 million in Q1 2026 from $46.8 million in Q1 2025.
- General and administrative expenses rose to $13.5 million in Q1 2026 from $10.1 million in Q1 2025.
- Closed IPO on March 2, 2026, issuing 25,000,000 shares and raising net proceeds of $369.3 million.
- All outstanding convertible preferred stock converted into 69,333,244 common shares post-IPO.
- Cash, cash equivalents, and marketable securities totaled $516.6 million as of March 31, 2026.
- Accumulated deficit reached $737.7 million as of March 31, 2026.